Mural Oncology plc Ordinary Shares (MURA) Dividend History

Mural Oncology plc is a biotechnology company focused on developing innovative cancer therapies. The company specializes in research and development initiatives aimed at improving treatment options for oncology patients. It leverages advanced scientific approaches to address unmet medical needs in the cancer treatment landscape.

10 Earlsfort Terrace, Dublin 2, L2, D02 T380
Phone: 353 1 905 8020
Website:

Dividend History

Mural Oncology plc Ordinary Shares currently does not pay dividends

Company News

  • Mural Oncology Announces Number of Relevant Securities in Issue

    Mural Oncology, a clinical-stage immuno-oncology company, announces plans to discontinue all clinical development of nemvaleukin following review of data from phase 2 and 3 trials. The company will explore strategic alternatives.

    GlobeNewswire Inc.
  • Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones

    Mural Oncology reported its Q4 2024 and full-year 2024 financial results, highlighting upcoming clinical milestones for its lead candidate nemvaleukin alfa in platinum-resistant ovarian cancer and mucosal melanoma. The company also announced two new development candidates, MURA-8518 and MURA-7012.

    GlobeNewswire Inc.
  • Mural Oncology to Participate in Two Upcoming Investor Conferences

    Mural Oncology, a clinical-stage immuno-oncology company, announced that members of its management team will participate in two upcoming investor conferences, the Jefferies London Healthcare Conference and the Piper Sandler 36th Annual Healthcare Conference.

    GlobeNewswire Inc.
  • Mural Oncology to Host First Virtual Investor Day on September 26, 2024

    Mural Oncology, a clinical-stage immuno-oncology company, will host a virtual Investor Day on September 26, 2024. The company will provide updates on its late-stage clinical candidate, nemvaleukin alfa, and its IL-18 pipeline program. Mural remains on track to deliver key data readouts in potentially registrational trials of nemvaleukin in platinum-resistant ovarian cancer and mucosal melanoma in the first half of 2025.

    GlobeNewswire Inc.
  • Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference

    WALTHAM, Mass. and DUBLIN, June 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that Caroline Loew, Ph.D., CEO, will present at the East Coast IDEAS Investor Conference on June 13 at 9:15 a.m. EST. A webcast will be available at www.threepartadvisors.com/east-coast and ir.muraloncology.com.

    GlobeNewswire Inc.
Dividend data last updated 06/07/2025 05:17:47 UTC